Simultaneous Multinuclear (Na+/H+) Metabolic MRI in Brain Tumors

Trial ID: NCT05045027

Interventional - Phase 1 - Active, not recruiting

This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.

Conditions

• Glioma
• Malignant Glioma
• Recurrent Glioma
• Recurrent Malignant Glioma

Interventions

• Biospecimen Collection
• Diagnostic Imaging
• Magnetic Resonance Imaging

Eligibility

Inclusion criteria

• AIM 1: Healthy volunteers with no evidence of brain tumors or neurologic disease
• AIM 1: Age 18+
• AIM 2: Newly diagnosed or recurrent suspected or confirmed glioma (low or high grade)
• AIM 2: 10 IDH mutant and 10 IDH wild type gliomas
• AIM 2: Clinically indicated for resective surgery or biopsy
• AIM 2: Age 18+
• AIM 2: Tumor size \> 1x1x1 cm (measurable)
• AIM 3: Recurrent glioma enrolled in an immunotherapy trial or clinically indicated to receive immunotherapy including anti-PD1
• AIM 3: Age 18+

Exclusion criteria

• AIM 1: Cannot safely perform an MRI
• AIM 1: Age \< 18
• AIM 2: Cannot safely perform an MRI or use of MRI contrast agents
• AIM 2: Age \< 18
• AIM 3: Cannot safely perform an MRI or use of MRI contrast agents
• AIM 3: Age \< 18

Sponsor

Jonsson Comprehensive Cancer Center, United States Department of Defense

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows